Buy Bromazolam Pellets 3mg

Product Overview

Bromazolam Pellets 3mg offers a high-purity triazolobenzodiazepine compound standardized in pellet format to support reproducible research workflows in analytical and industrial laboratories. Identified by CAS 71368-80-4, Bromazolam is recognized as a non-marketed benzodiazepine analog used in reference libraries, forensic toxicology, and method development for the detection of emerging psychoactive substances. This product is supplied as a brandless, ≥98% purity research chemical, providing a reliable option for laboratories requiring consistent solid-state units that are easy to track, store, and integrate into validated procedures.

The pelletized 3mg format helps support accurate portioning, minimizing weighing error and enhancing workflow efficiency where repeatability and traceability are important. Its solid-state stability and clear identity data make it appropriate for internal standards, reference calibrators, and quality control samples in non-clinical environments. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

Chemical Identity & Classification

Bromazolam is defined by CAS number 71368-80-4 and the molecular formula C17H13BrN4, with a molecular weight of approximately 353.2 g/mol. It is structurally described by the IUPAC name 8-bromo-1-methyl-6-phenyl-4H-triazolo[4,3-a]benzodiazepine, placing it in the triazolobenzodiazepine (TBZD) subclass. Common synonyms in scientific and regulatory literature include XLI-268, DE(chloro)-bromo-alprazolam, and UNII-YMC9OT97Z1, all referencing the same core scaffold.

As a chemical entity, Bromazolam functions in the marketplace as an analytical reference standard and research-only benzodiazepine analog, not as a finished pharmaceutical product. It is often cataloged under categories such as “forensic reference materials,” “novel psychoactive substance standards,” and “research benzodiazepines,” reflecting its typical application in non-clinical analytical chemistry, toxicology, and structural studies.

Chemical & Physical Characteristics

Bromazolam is generally supplied as a crystalline solid, typically off-white to light-colored, consistent with many benzodiazepine and triazolobenzodiazepine compounds. In its pure form, it exhibits a defined molecular structure with documented 2D and 3D conformations, which can be used in computational modeling, spectral correlation, and method development. Computed properties indicate a molecular weight of 353.2 g/mol and a lipophilicity (XLogP3) typical of benzodiazepine analogs, supporting its behavior in organic solvent systems and chromatographic separations.

Solubility data indicate that Bromazolam dissolves effectively in DMSO at around 5 mg/mL, with additional solubility in other polar aprotic organic solvents such as DMF and partial solubility in ethanol. As with many hydrophobic aromatic heterocycles, its solubility in purely aqueous media is limited, so it is often handled using co-solvent systems during analytical preparation. Under standard conditions, Bromazolam is a low-volatility, non-volatile solid with stable performance when stored correctly, allowing reliable integration into solid-state formats such as pellets.

Purity & Analytical Verification

Bromazolam Pellets 3mg are manufactured to meet or exceed a purity specification of 98%, suitable for demanding analytical and quality-control applications. Purity assessment generally employs orthogonal analytical techniques such as High-Performance Liquid Chromatography (HPLC), Nuclear Magnetic Resonance (NMR) spectroscopy, Liquid Chromatography-Mass Spectrometry (LC-MS), and complementary chromatographic methods to characterize both the main peak and potential related substances.

These assays support confirmation of identity, assessment of residual solvents, and quantification of trace impurities to ensure batch-to-batch consistency. A Certificate of Analysis (COA) for Bromazolam typically includes chromatograms, spectral data, molecular weight confirmation, and assay results, providing researchers with the documentation needed for internal qualification, method validation, and regulatory documentation in non-clinical research settings.

Quality Control & Batch Integrity

Production of Bromazolam as a research chemical is typically executed under tightly controlled conditions aligned with best practices for analytical standards, including traceable raw materials and documented synthesis steps. Each batch is assigned a unique lot number that links synthesis, purification, testing, and final packaging, enabling full traceability across the product lifecycle. Batch records normally capture key parameters such as yield, purity, residual solvent levels, and verification of structural identity to maintain a consistent quality profile.

In addition to internal testing, quality programs may incorporate periodic third-party verification for identity and purity, helping to confirm that materials remain aligned with published specifications and reference data. Retained samples are often stored under controlled conditions to support re-testing and long-term stability evaluation if required by the end user or internal quality management systems. This structured approach is designed to provide laboratories with a dependable, reproducible reference material for analytical applications.

Safety, Handling & Laboratory Precautions

Bromazolam, like other benzodiazepine analogs handled as research chemicals, is subject to hazard classification under chemical safety frameworks and should be managed only by trained personnel in appropriate laboratory environments. Safety documentation such as Safety Data Sheets (SDS) describes hazard statements that can include acute toxicity and other risk categories, guiding the use of protective equipment and procedural safeguards.

Standard laboratory practice for handling such solids includes working in a fume hood or equivalent engineering control, wearing suitable personal protective equipment (PPE) such as gloves, safety glasses or goggles, and lab coats, and preventing dust or aerosol formation during weighing or transfer. Any spills or accidental releases should be managed according to institutional hazardous material procedures, with reference to the SDS for appropriate containment, cleanup methods, and disposal channel selection.

Packaging, Labeling & Storage

Bromazolam Pellets 3mg are suited to packaging formats that protect against moisture, light, and cross-contamination, such as sealed vials, jars, or blister configurations, depending on the supplier’s packaging design. Packaging typically carries clear labeling including product name, CAS number (71368-80-4), batch or lot number, purity statement, and explicit “Research Use Only” indications to help maintain regulatory compliance and correct internal classification.

Storage recommendations for Bromazolam commonly involve keeping the material in a cool, dry, and well-ventilated place away from incompatible substances, with some suppliers specifying refrigerated or sub-ambient conditions (for example, around -20°C) to maximize stability over the shelf life. Containers should remain tightly closed when not in use to reduce the risk of environmental exposure and degradation.

Intended Research Use & Market Positioning

Bromazolam Pellets 3mg are intended for use in analytical chemistry, forensic toxicology, industrial R&D, and related research fields where triazolobenzodiazepine reference materials are required. Typical applications include calibration of LC-MS or GC-MS methods, inclusion in reference libraries, evaluation of detection limits and specificity for benzodiazepine screening panels, and structural or spectral comparison studies.

In the research chemical market, Bromazolam is regarded as a non-marketed analog of established benzodiazepines, and is valued for its defined structure and documented properties rather than for any clinical application. This positions Bromazolam Pellets 3mg as a technical resource for laboratories focusing on method development, compound characterization, and non-clinical investigation of benzodiazepine-class molecules under controlled conditions.

Ordering, Availability & Fulfillment

Bromazolam as a reference chemical is offered internationally by specialized suppliers that focus on analytical standards and research-grade reagents. When integrated into an eCommerce platform, Bromazolam Pellets 3mg can be made available through secure online ordering with encrypted checkout and order confirmation workflows suitable for regulated environments. Stock management practices typically ensure that active lots with valid COAs and retest dates are selected for fulfillment, simplifying audit trails and internal documentation for the purchasing laboratory.

Orders are generally shipped via tracked services, with packaging designed to keep the product stable throughout transit and to align with carrier and customs requirements for chemical reagents. Customer support is usually available to provide access to COAs, SDS documentation, and basic product documentation to assist technical staff and quality personnel during onboarding and method integration.

Legal & Regulatory Disclaimer

Bromazolam Pellets 3mg is supplied strictly as a research chemical and reference material and is not approved for use as a drug, dietary ingredient, clinical agent, or any form of consumable product. End users are responsible for ensuring that the possession, handling, and use of this compound comply with all relevant local, national, and international laws, including any scheduling, reporting, or registration requirements that may apply in their jurisdiction. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.